Hjem › Migrene › North Carolina
Kliniske studier for Migrene i North Carolina
12 studier for Migrene søker deltakere på steder i North Carolina.
Byer i North Carolina
Offisiell studietekst (engelsk)
Study of EVO756 in Adults With Migraine
- Asheville Neurology Specialists, Pa, Asheville
- Eximia Research NC, Raleigh
RekruttererFase 2
Alder 18 til 64 · Alle kjønn · Oppdatert 2. okt. 2026 · NCT07616128A Study to Learn About the Study Medicine Called Zavegepant (PF-07930207) in Children With a History of Migraine
- Accellacare - Piedmont, Statesville
- Accellacare of Piedmont HealthCare, Statesville
- Accellacare US Inc., Winston-Salem
RekruttererFase 1
Alder 6 til 11 · Alle kjønn · Oppdatert 28. sep. 2026 · NCT06995729Long-term Safety Study of Rimegepant in Pediatric Subjects for the Acute Treatment of Migraine
- OnSite Clinical Solutions, LLC, Charlotte
RekruttererFase 3
Alder 6 til 17 · Alle kjønn · Oppdatert 24. sep. 2026 · NCT04743141Randomized Study in Children and Adolescents With Migraine: Acute Treatment
- OnSite Clinical Solutions, LLC, Charlotte
RekruttererFase 3
Alder 6 til 17 · Alle kjønn · Oppdatert 24. sep. 2026 · NCT04649242Comparative Effectiveness of Migraine Preventive Medications: The APT Comparison Study
- Onsite Clinical Solutions Park Cedar Dr., Charlotte
- Onsite Clinical Solutions Mecklenburg, Charlotte
- Onsite Clinical Solutions Ballantyne, Charlotte
- og 2 flere
RekruttererFase 4
Alder 18 til 70 · Alle kjønn · Oppdatert 16. sep. 2026 · NCT06972056Study to Assess Adverse Events and Disease Activity of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17)
- Onsite Clinical Solutions - Don Lochman Lane - Charlotte /ID# 282834, Charlotte
RekruttererFase 3
Alder 6 til 17 · Alle kjønn · Oppdatert 14. sep. 2026 · NCT05125302A Pivotal Clinical Study to Evaluate the MySalvia System for the Treatment of Resistant Migraine
- Queen City Clinical Research, PLLC, Charlotte
Rekrutterer
Alder 22 til 84 · Alle kjønn · Oppdatert 28. aug. 2026 · NCT07719608A Study to Evaluate the Efficacy and Safety of Elismetrep (K-304) in the Acute Treatment of Migraine
- OnSite Clinical Solutions, Charlotte
- Guildford Neurologic Research Partners, LLC, Greensboro
- Headache Wellness Center, Greensboro
- og 2 flere
RekruttererFase 3
Alder 18 til 75 · Alle kjønn · Oppdatert 20. aug. 2026 · NCT07645924BE WELL With Migraine: Brain Education and WELLness With Migraine
- Wake Forest University Health Sciences, Winston-Salem
Rekrutterer
Alder 18 og eldre · Alle kjønn · Oppdatert 12. jun. 2026 · NCT05987592Observational Study to Assess Maternal, Fetal and Infant Outcomes Following Exposure to Rimegepant
- Evidera, a PPD business unit, Wilmington
RekruttererObservasjonsstudie
Alder 0 og eldre · Kvinner · Oppdatert 5. mai 2026 · NCT05046613Observational Study to Assess Adverse Events When Adult Female Participants Are Treated With Ubrelvy (Ubrogepant) or Qulipta (Atogepant) During Pregnancy
- Iqvia /Id# 266904, Durham
RekruttererObservasjonsstudie
Alder 18 og eldre · Kvinner · Oppdatert 15. des. 2025 · NCT05158894Aimovig Pregnancy Exposure Registry
- IQVIA Virtual Site, Durham
RekruttererObservasjonsstudieFrivillige helsepersonell ønskes velkommen
Alder 18 til 99 · Kvinner · Oppdatert 4. nov. 2025 · NCT06150781Fra ClinicalTrials.gov, data hentet 5. okt. 2026. Hver studie setter sine egne kvalifikasjonskrav; studieteamet avgjør hvem som kan delta.